1. What Is the Dengue Market?
The Dengue Market covers the vaccines and the supportive care management for the dengue virus infection transmitted by the Aedes aegypti mosquito. The infection causes 390 million annual dengue infections globally with the 96 million symptomatic cases. The severe dengue produces the plasma leakage, the haemorrhage, and the organ failure. Dengue pharmacological treatment has no approved antiviral and relies on the supportive care of the fluid management, the antipyretics, and the clinical monitoring for the warning signs that precede the severe dengue. The dengue market is advancing with the TAK-003 Phase III TIDES trial demonstrating 80.2 percent dengue efficacy at 12 months across the seronegative and seropositive populations. The live-attenuated tetravalent dengue vaccine does not require the pre-vaccination serostatus screening. The earlier dengue vaccine's risk of enhanced disease in the seronegative recipient required the screening.
2. Dengue Market Size & Forecast
3. Emerging Technologies
- Dengvaxia Sanofi Pasteur CYD-TDV tetravalent dengue vaccine IDEVAL and CYDECT Phase III demonstrated 59.2 percent dengue efficacy in the 9 to 16-year seropositive children. The trials showed the increased severe dengue risk in the seronegative recipients under 9 years. The pre-vaccination dengue serology screening requirement limits the Dengvaxia deployment to the seropositive confirmed patient in the endemic country.
- Qdenga TAK-003 TIDES Phase III demonstrated 80.2 percent symptomatic dengue efficacy at 12 months without the pre-vaccination serostatus screening requirement. The live-attenuated tetravalent backbone uses the dengue serotype 2. The backbone does not enhance the disease in the seronegative recipient.
- Dengue plasma leakage critical phase management uses the fluid therapy replacement of the 5 to 10 percent plasma volume deficit. The vascular permeability increase from the NS1 protein interaction with the endothelial glycocalyx creates the deficit during the defervescence phase. The fluid resuscitation prevents the hypovolemic shock.
- Dengue antiviral pipeline includes the celgosivir iminosugar and the JNJ-64281802 NS5 polymerase inhibitor. These provide the investigational mechanisms for the dengue antiviral. The supportive care management currently lacks the approved antiviral.
Similar technologies are also transforming adjacent markets. Learn more in our Ebola Market.
4. Key Market Opportunity
Substantial growth potential in the Dengue market is Qdenga vaccine market expansion through broader indication adoption in endemic regions and expanding non-endemic markets affected by climate change. Takeda capturing growing Qdenga prescribing reflects this expansion opportunity. Additional momentum is centered on dengue antiviral development for treatment of established infection. As Qdenga adoption proceeds and dengue antiviral development advances, the addressable opportunity is expanding from prevention-only dengue management toward both vaccination and antiviral therapy.
5. Top Companies in the Dengue Market
The following organisations hold leading positions in the Dengue Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Sanofi
- Takeda
- Merck
- Johnson and Johnson
- GSK
- Cipla
- Sun Pharma
6. Market Segmentation
The Dengue Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Product Type | Vaccine Antiviral Supportive Care |
| By Vaccine | Dengvaxia Qdenga |
| By Population | Pediatric Adult |
| By Setting | Endemic Travel Outbreak |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Dengue Market trajectory over the forecast period:
Qdenga TAK-003 TIDES Phase III 80.2 Percent Symptomatic Dengue Efficacy Without Pre-Vaccination Serostatus Screening Requirement Has Overcome the Dengvaxia Enhanced Disease Risk in Seronegative Recipients That Limited Dengvaxia to Seropositive Confirmed Patients Only.Takeda's dengue vaccine TAK-003 demonstrated 80.2% vaccine efficacy against virologically confirmed dengue disease at 12 months and 61.2% efficacy against hospitalised dengue in TIDES across endemic countries in Asia and Latin America in a mixed seropositive and seronegative population, achieving the broader applicability than Dengvaxia's seropositive-restricted indication that had limited Sanofi's commercial reach. The 2-dose schedule at 0 and 3 months enables school-based vaccination programme integration, and the absence of a pre-vaccination serostatus testing requirement removes the logistical complexity that prevented Dengvaxia's mass deployment in settings without healthcare infrastructure for blood testing. National immunisation programmes in Indonesia, Argentina, Brazil, and Thailand are incorporating Qdenga into routine childhood vaccination schedules for the 9-16 year age group where dengue severity peaks during the secondary heterotypic infection that occurs in the 8-12 year post-primary-infection window.
Dengvaxia Pre-Vaccination Serology Screening Requirement From Enhanced Severe Dengue Risk in Seronegative Under-9 Recipients Has Established the Serostatus-Dependent Vaccine Eligibility Framework That Limits the Universal Dengue Vaccination Programme to the Confirmed Seropositive Population.Sanofi's dengvaxia experience in the Philippines where 830,000 schoolchildren received the vaccine before the serostatus restriction was implemented revealed that dengue-naive vaccinees experience a higher risk of severe dengue when subsequently infected, leading to criminal charges against Sanofi executives, vaccine hesitancy in the Philippines, and WHO policy requiring serostatus testing or seroprevalence threshold above 70% before population-level dengue vaccination programmes. The immunological mechanism involves dengvaxia effectively acting as a primary infection in dengue-naive recipients, priming a subsequent natural infection to behave as an immunologically enhanced secondary infection with the antibody-dependent enhancement that drives dengue haemorrhagic fever in seropositive individuals experiencing heterotypic reinfection. The dengvaxia episode has defined dengue vaccine risk communication standards globally and established that pre-vaccination seroprevalence data is an absolute requirement for policy decisions about population-wide dengue vaccination programmes that use any dengue vaccine candidate.
Dengue NS1 Protein Endothelial Glycocalyx Disruption Creating Plasma Leakage During Defervescence Critical Phase Has Established the Fluid Resuscitation Timing and Volume Management as the Life-Saving Supportive Care Preventing Hypovolemic Shock in Severe Dengue Without an Approved Antiviral.World Mosquito Program's Wolbachia-infected Aedes aegypti mosquito release in Yogyakarta Indonesia demonstrated 77.1% dengue incidence reduction in the intervention zones versus control zones in AWED, providing the first randomised controlled evidence that environmental Wolbachia deployment achieves sustained transmission blocking at the community level. The Wolbachia mechanism involves the intracellular bacteria reducing dengue virus replication in infected mosquitoes to a level below the transmissible threshold, preventing onward dengue transmission to humans when the Wolbachia mosquito fraction in the local population exceeds approximately 40%. Multi-country scaling through WMP's Singapore, Brazil, Australia, and Fiji programmes is generating epidemiology data to inform WHO's position on Wolbachia as a complementary intervention to dengue vaccination, and the two approaches' complementary mechanisms create potential for additive impact in high-burden endemic settings where both strategies are deployed simultaneously.
For related market intelligence, see the Zika Market.
8. Segmental Analysis
By product type, the dengue vaccine segment dominated the Dengue Market in 2025, as Takeda's Qdenga achieved regulatory approval across multiple endemic markets and Sanofi's Dengvaxia served its seropositive-limited population, generating the dominant share of commercial dengue products.
By population, the endemic and adolescent segment is projected to register the highest growth rate through 2034, as Qdenga expands vaccination programmes across Southeast Asia and Latin America and Merck and other developers advance additional vaccine candidates for the large unprotected paediatric and adult population.
9. Regional Analysis
Regional demand patterns across the Dengue Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
Asia Pacific dominated the Dengue Market in 2025, accounting for approximately 40% of patient volume and procurement, attributed to the very large dengue disease burden in Southeast Asia, India, and other dengue-endemic Asia Pacific countries. Moreover, Qdenga adoption is most advanced in endemic Asia Pacific markets. In addition, dengue surveillance and outbreak response programmes are concentrated in the region. Regional dominance is due to this combination of disease burden and vaccine adoption.
Highest CAGR Region
Latin America is projected to register the highest CAGR in the Dengue Market through 2034, driven by the large dengue disease burden in Brazil and other Latin American countries and expanding Qdenga vaccine adoption alongside dengue outbreak response. The region is also witnessing dengue antiviral clinical trial participation. Moreover, climate-driven dengue expansion is increasing disease burden. The combination of these demand drivers and disease burden positions Latin America for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Dengue Market was valued at USD 477.70 Mn in 2025 and is projected to reach USD 1,654.40 Mn by 2034, growing at a CAGR of 14.8% over the 2026–2034 forecast period.
The Dengue Market is projected to grow at a CAGR of 14.8% from 2026 to 2034.
Asia Pacific dominated the Dengue Market in 2025, accounting for approximately 40% of patient volume and procurement, attributed to the very large dengue disease burden in Southeast Asia, India, and other dengue-endemic Asia Pacific countries.
The leading companies in the Dengue Market include Sanofi, Takeda, Merck, Johnson and Johnson, GSK, Cipla, Sun Pharma.
Qdenga tak-003 tides phase iii 80.2 percent symptomatic dengue efficacy without pre-vaccination serostatus screening requirement has overcome the dengvaxia enhanced disease risk in seronegative recipients that limited dengvaxia to seropositive confirmed patients only.
By product type, the dengue vaccine segment dominated the Dengue Market in 2025, as Takeda's Qdenga achieved regulatory approval across multiple endemic markets and Sanofi's Dengvaxia served its seropositive-limited population, generating the dominant share of commercial dengue products.
How to Order
Choose Your Package
Who competes in this market, how large each player is, and where they sit against each other.
- Business overview, HQ, headcount & ownership
- Product and brand portfolio mapped per company
- Recent developments: launches, M&A, partnerships, capacity
- SWOT and strategic posture for each player
- 2025 market share split by company, plus “others”
- Company revenue mapping in USD Mn
- Competitive landscape matrix & quadrant positioning
- Concentration read: top-5 share and fragmentation
The forecast model itself. Every table from the study as clean, formula-ready Excel across 4 segmentation axes. Choose how much geography you need.
- One country, broken out across 4 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 4 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack (Package 2.3)
- Complete research methodology, assumptions & appendix
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.